ERBB4 confers metastatic capacity in Ewing sarcoma

Ariadna Mendoza-Naranjo, Amal El-Naggar, Daniel H. Wai, Priti Mistry, Nikola Lazic, Fernanda Rocha Rojas Ayala, Isabela Werneck da Cunha, Pablo Rodriguez-Viciana, Hongwei Cheng, Jose H. Tavares Guerreiro Fregnani, Patrick Reynolds, Robert J. Arceci, Andrew Nicholson, Timothy J. Triche, Fernando A. Soares, Adrienne M. Flanagan, Yuzhuo Z. Wang, Sandra J. Strauss, Poul H. Sorensen

Research output: Contribution to journalArticle

Abstract

Metastatic spread is the single-most powerful predictor of poor outcome in Ewing sarcoma (ES). Therefore targeting pathways that drive metastasis has tremendous potential to reduce the burden of disease in ES. We previously showed that activation of the ERBB4 tyrosine kinase suppresses anoikis, or detachment-induced cell death, and induces chemoresistance in ES cell lines in vitro. We now show that ERBB4 is transcriptionally overexpressed in ES cell lines derived from chemoresistant or metastatic ES tumours. ERBB4 activates the PI3K-Akt cascade and focal adhesion kinase (FAK), and both pathways contribute to ERBB4-mediated activation of the Rac1 GTPase in vitro and in vivo. ERBB4 augments tumour invasion and metastasis in vivo, and these effects are blocked by ERBB4 knockdown. ERBB4 expression correlates significantly with reduced disease-free survival, and increased expression is observed in metastatic compared to primary patient-matched ES biopsies. Our findings identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease in ES. These results predict that therapeutic targeting of ERBB4, alone or in combination with cytotoxic agents, may suppress the metastatic phenotype in ES. The Authors show that ERBB4 is a biological driver of metastasis in the pediatric bone tumour Ewing sarcoma and identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease.

Original languageEnglish (US)
Pages (from-to)1019-1034
Number of pages16
JournalEMBO Molecular Medicine
Volume5
Issue number7
DOIs
StatePublished - Jul 2013

Fingerprint

Ewing's Sarcoma
Focal Adhesion Protein-Tyrosine Kinases
Phosphatidylinositol 3-Kinases
Neoplasm Metastasis
Anoikis
Cell Line
GTP Phosphohydrolases
Cytotoxins
Protein-Tyrosine Kinases
Disease-Free Survival
Neoplasms
Cell Death
Pediatrics
Phenotype
Biopsy
Bone and Bones

Keywords

  • ERBB4
  • Ewing sarcoma
  • FAK
  • Metastasis
  • Rac1

ASJC Scopus subject areas

  • Molecular Medicine

Cite this

Mendoza-Naranjo, A., El-Naggar, A., Wai, D. H., Mistry, P., Lazic, N., Ayala, F. R. R., ... Sorensen, P. H. (2013). ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Molecular Medicine, 5(7), 1019-1034. https://doi.org/10.1002/emmm.201202343

ERBB4 confers metastatic capacity in Ewing sarcoma. / Mendoza-Naranjo, Ariadna; El-Naggar, Amal; Wai, Daniel H.; Mistry, Priti; Lazic, Nikola; Ayala, Fernanda Rocha Rojas; da Cunha, Isabela Werneck; Rodriguez-Viciana, Pablo; Cheng, Hongwei; Tavares Guerreiro Fregnani, Jose H.; Reynolds, Patrick; Arceci, Robert J.; Nicholson, Andrew; Triche, Timothy J.; Soares, Fernando A.; Flanagan, Adrienne M.; Wang, Yuzhuo Z.; Strauss, Sandra J.; Sorensen, Poul H.

In: EMBO Molecular Medicine, Vol. 5, No. 7, 07.2013, p. 1019-1034.

Research output: Contribution to journalArticle

Mendoza-Naranjo, A, El-Naggar, A, Wai, DH, Mistry, P, Lazic, N, Ayala, FRR, da Cunha, IW, Rodriguez-Viciana, P, Cheng, H, Tavares Guerreiro Fregnani, JH, Reynolds, P, Arceci, RJ, Nicholson, A, Triche, TJ, Soares, FA, Flanagan, AM, Wang, YZ, Strauss, SJ & Sorensen, PH 2013, 'ERBB4 confers metastatic capacity in Ewing sarcoma', EMBO Molecular Medicine, vol. 5, no. 7, pp. 1019-1034. https://doi.org/10.1002/emmm.201202343
Mendoza-Naranjo A, El-Naggar A, Wai DH, Mistry P, Lazic N, Ayala FRR et al. ERBB4 confers metastatic capacity in Ewing sarcoma. EMBO Molecular Medicine. 2013 Jul;5(7):1019-1034. https://doi.org/10.1002/emmm.201202343
Mendoza-Naranjo, Ariadna ; El-Naggar, Amal ; Wai, Daniel H. ; Mistry, Priti ; Lazic, Nikola ; Ayala, Fernanda Rocha Rojas ; da Cunha, Isabela Werneck ; Rodriguez-Viciana, Pablo ; Cheng, Hongwei ; Tavares Guerreiro Fregnani, Jose H. ; Reynolds, Patrick ; Arceci, Robert J. ; Nicholson, Andrew ; Triche, Timothy J. ; Soares, Fernando A. ; Flanagan, Adrienne M. ; Wang, Yuzhuo Z. ; Strauss, Sandra J. ; Sorensen, Poul H. / ERBB4 confers metastatic capacity in Ewing sarcoma. In: EMBO Molecular Medicine. 2013 ; Vol. 5, No. 7. pp. 1019-1034.
@article{0c162aa221cb47189ce6bf940e112d6f,
title = "ERBB4 confers metastatic capacity in Ewing sarcoma",
abstract = "Metastatic spread is the single-most powerful predictor of poor outcome in Ewing sarcoma (ES). Therefore targeting pathways that drive metastasis has tremendous potential to reduce the burden of disease in ES. We previously showed that activation of the ERBB4 tyrosine kinase suppresses anoikis, or detachment-induced cell death, and induces chemoresistance in ES cell lines in vitro. We now show that ERBB4 is transcriptionally overexpressed in ES cell lines derived from chemoresistant or metastatic ES tumours. ERBB4 activates the PI3K-Akt cascade and focal adhesion kinase (FAK), and both pathways contribute to ERBB4-mediated activation of the Rac1 GTPase in vitro and in vivo. ERBB4 augments tumour invasion and metastasis in vivo, and these effects are blocked by ERBB4 knockdown. ERBB4 expression correlates significantly with reduced disease-free survival, and increased expression is observed in metastatic compared to primary patient-matched ES biopsies. Our findings identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease in ES. These results predict that therapeutic targeting of ERBB4, alone or in combination with cytotoxic agents, may suppress the metastatic phenotype in ES. The Authors show that ERBB4 is a biological driver of metastasis in the pediatric bone tumour Ewing sarcoma and identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease.",
keywords = "ERBB4, Ewing sarcoma, FAK, Metastasis, Rac1",
author = "Ariadna Mendoza-Naranjo and Amal El-Naggar and Wai, {Daniel H.} and Priti Mistry and Nikola Lazic and Ayala, {Fernanda Rocha Rojas} and {da Cunha}, {Isabela Werneck} and Pablo Rodriguez-Viciana and Hongwei Cheng and {Tavares Guerreiro Fregnani}, {Jose H.} and Patrick Reynolds and Arceci, {Robert J.} and Andrew Nicholson and Triche, {Timothy J.} and Soares, {Fernando A.} and Flanagan, {Adrienne M.} and Wang, {Yuzhuo Z.} and Strauss, {Sandra J.} and Sorensen, {Poul H.}",
year = "2013",
month = "7",
doi = "10.1002/emmm.201202343",
language = "English (US)",
volume = "5",
pages = "1019--1034",
journal = "EMBO Molecular Medicine",
issn = "1757-4676",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - ERBB4 confers metastatic capacity in Ewing sarcoma

AU - Mendoza-Naranjo, Ariadna

AU - El-Naggar, Amal

AU - Wai, Daniel H.

AU - Mistry, Priti

AU - Lazic, Nikola

AU - Ayala, Fernanda Rocha Rojas

AU - da Cunha, Isabela Werneck

AU - Rodriguez-Viciana, Pablo

AU - Cheng, Hongwei

AU - Tavares Guerreiro Fregnani, Jose H.

AU - Reynolds, Patrick

AU - Arceci, Robert J.

AU - Nicholson, Andrew

AU - Triche, Timothy J.

AU - Soares, Fernando A.

AU - Flanagan, Adrienne M.

AU - Wang, Yuzhuo Z.

AU - Strauss, Sandra J.

AU - Sorensen, Poul H.

PY - 2013/7

Y1 - 2013/7

N2 - Metastatic spread is the single-most powerful predictor of poor outcome in Ewing sarcoma (ES). Therefore targeting pathways that drive metastasis has tremendous potential to reduce the burden of disease in ES. We previously showed that activation of the ERBB4 tyrosine kinase suppresses anoikis, or detachment-induced cell death, and induces chemoresistance in ES cell lines in vitro. We now show that ERBB4 is transcriptionally overexpressed in ES cell lines derived from chemoresistant or metastatic ES tumours. ERBB4 activates the PI3K-Akt cascade and focal adhesion kinase (FAK), and both pathways contribute to ERBB4-mediated activation of the Rac1 GTPase in vitro and in vivo. ERBB4 augments tumour invasion and metastasis in vivo, and these effects are blocked by ERBB4 knockdown. ERBB4 expression correlates significantly with reduced disease-free survival, and increased expression is observed in metastatic compared to primary patient-matched ES biopsies. Our findings identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease in ES. These results predict that therapeutic targeting of ERBB4, alone or in combination with cytotoxic agents, may suppress the metastatic phenotype in ES. The Authors show that ERBB4 is a biological driver of metastasis in the pediatric bone tumour Ewing sarcoma and identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease.

AB - Metastatic spread is the single-most powerful predictor of poor outcome in Ewing sarcoma (ES). Therefore targeting pathways that drive metastasis has tremendous potential to reduce the burden of disease in ES. We previously showed that activation of the ERBB4 tyrosine kinase suppresses anoikis, or detachment-induced cell death, and induces chemoresistance in ES cell lines in vitro. We now show that ERBB4 is transcriptionally overexpressed in ES cell lines derived from chemoresistant or metastatic ES tumours. ERBB4 activates the PI3K-Akt cascade and focal adhesion kinase (FAK), and both pathways contribute to ERBB4-mediated activation of the Rac1 GTPase in vitro and in vivo. ERBB4 augments tumour invasion and metastasis in vivo, and these effects are blocked by ERBB4 knockdown. ERBB4 expression correlates significantly with reduced disease-free survival, and increased expression is observed in metastatic compared to primary patient-matched ES biopsies. Our findings identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease in ES. These results predict that therapeutic targeting of ERBB4, alone or in combination with cytotoxic agents, may suppress the metastatic phenotype in ES. The Authors show that ERBB4 is a biological driver of metastasis in the pediatric bone tumour Ewing sarcoma and identify a novel ERBB4-PI3K-Akt-FAK-Rac1 pathway associated with aggressive disease.

KW - ERBB4

KW - Ewing sarcoma

KW - FAK

KW - Metastasis

KW - Rac1

UR - http://www.scopus.com/inward/record.url?scp=84880019478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880019478&partnerID=8YFLogxK

U2 - 10.1002/emmm.201202343

DO - 10.1002/emmm.201202343

M3 - Article

C2 - 23681745

AN - SCOPUS:84880019478

VL - 5

SP - 1019

EP - 1034

JO - EMBO Molecular Medicine

JF - EMBO Molecular Medicine

SN - 1757-4676

IS - 7

ER -